• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Johnson & Johnson sees global pharma sales climb 20% in Q2

July 17, 2018 By Sarah Faulkner

Johnson & JohnsonHealthcare giant Johnson & Johnson (NYSE:JNJ) today topped sales and earnings estimates with its second-quarter financial results, posting sales growth of 19.9% for its pharmaceutical segment compared to the same period last year.

The New Brunswick, N.J.-based company reported overall profit growth of 3.1% to $3.95 billion, or $1.45 per share, on sales of $20.83 billion for the three months ended June 30.

Adjusted to exclude one-time items, earnings per share were $2.10, ahead of the consensus on Wall Street, where analysts were looking for sales of $20.39 billion.

Global sales for its pharma unit grew nearly 20% to reach $10.4 billion in the second quarter, Johnson & Johnson reported. The company noted that its domestic sales were up 17.7% and international sales were up 22.9%.

Johnson & Johnson attributed the success of its pharmaceutical segment to a number of products, including Stelara, a biologic indicated to treat immune-mediated inflammatory diseases, and its oral anticoagulant, Xarelto.

The company also nabbed a number of regulatory wins during the quarter. The FDA approved added indications for Johnson & Johnson’s multiple myeloma drug, Darzalex, including its use in combination with a proteasome inhibitor and prednisone. The company also touted that its two-drug regimen, once-daily, single-pill HIV therapy won marketing authorization in the European Union.

“Our strong second-quarter results reflect double-digit growth in our pharmaceutical business and the accelerating sales momentum in our medical devices business, driven by the continued growth of our market leading products and strategic new launches. We remain focused on investing in innovation and meeting the needs of our customers by delivering innovative products and solutions that position the company to deliver long-term, sustainable growth,” chairman & CEO Alex Gorsky said in prepared remarks.

JNJ shares were trading at $125.80 in premarket activity today, up +0.9%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS